Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Long-Term Deferred Tax (2019 - 2025)

Maxcyte has reported Long-Term Deferred Tax over the past 3 years, most recently at $945000.0 for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 38.11% to $945000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $945000.0 through Dec 2025, down 38.11% year-over-year, with the annual reading at $945000.0 for FY2025, 38.11% down from the prior year.
  • Long-Term Deferred Tax was $945000.0 for Q4 2025 at Maxcyte, down from $1.5 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $1.5 million in Q4 2024 and troughed at $945000.0 in Q4 2025.